The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial
NCT ID: NCT02525198
Last Updated: 2024-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
259 participants
INTERVENTIONAL
2015-08-01
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Flavonoid Supplementation on Cognition and Neural Mechanisms in Healthy Older Adults
NCT03030053
Effects of Flavonoids on Cognitive Performance in Healthy Young Adults
NCT01312597
Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults
NCT01620567
The Effects of a Combination of Nootropic Ingredients on Cognition in Healthy Young Volunteers
NCT02857829
Nutraceutical Effects on Long-Term Memory
NCT01963767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be asked to take the study food each day for 12 months, and to come to the clinical assessment unit on 3 occasions, at baseline, 3 months and 12 months, to complete a cognitive task battery such that their performance may be investigated in the context of the intervention.
Urine, blood and faecal samples will be collected and magnetic resonance imaging (MRI) will be applicable to half of each population (i.e to 60 MCI and 60 SCI, 30 of each at Norwich and Melbourne).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
Placebo
see arm description
fatty acid/flavonoid blend
Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
fatty acid/flavonoid blend
see arm description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fatty acid/flavonoid blend
see arm description
Placebo
see arm description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild cognitive impairment (MCI) or subjective memory impairment (SMI) with no indication of clinical dementia or depression
* Willing and able to provide written informed consent.
* Understands and is willing and able to comply with all study procedures.
* Fluent in written and spoken English.
* In good general health including blood biochemical, haematological and urinalysis within the normal range at screening (as judged by the clinical advisor)
* Normal, or corrected to normal vision and hearing
* Right handed, for MRI
* Stable use of any prescribed medication for at least four weeks
Exclusion Criteria
* Parent or sibling who developed premature dementia \<60y (suggestive of a familial monogenic form of cognitive decline)
* Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness \> 24 hours
* History of alcohol or drug dependency within the last 2 years
* Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser)
* Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser)
* Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months
* Carotid stents or severe stenosis
* Known allergy to fish or any other component in the intervention supplements
* Existing medical conditions likely to affect the study measures (as judged by clinical adviser)
* Uncontrolled hypertension (Systolic Blood Pressure (SBP) \>140mmHg, Diastolic Blood Pressure (DBP) \>90mmHg)
* BMI \>40kg/m2
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swinburne University of Technology
OTHER
University of Illinois at Chicago
OTHER
University of East Anglia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Marie Minihane, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Nutrition, University of East Anglia, Norwich, U.K.
Andrew Scholey, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre for Human Psychopharmacology, Swinburne University of Technology
Neal J Cohen, PhD
Role: PRINCIPAL_INVESTIGATOR
Beckman Institute, University of Illinois
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beckman Institute, University of Illinois
Urbana, Illinois, United States
Centre for Human Psychopharmacology, Swinburne Univerity of Technology
Melbourne, Victoria, Australia
Department of Nutrition, University of East Anglia
Norwich, Norfolk, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vauzour D, Scholey A, White DJ, Cohen NJ, Cassidy A, Gillings R, Irvine MA, Kay CD, Kim M, King R, Legido-Quigley C, Potter JF, Schwarb H, Minihane AM. A combined DHA-rich fish oil and cocoa flavanols intervention does not improve cognition or brain structure in older adults with memory complaints: results from the CANN randomized, controlled parallel-design study. Am J Clin Nutr. 2023 Aug;118(2):369-381. doi: 10.1016/j.ajcnut.2023.06.008. Epub 2023 Jun 12.
Irvine MA, Scholey A, King R, Gillings R, Vauzour D, Demichele SJ, Das T, Wesnes KA, Sutton BP, Cassidy A, Pipingas A, Potter JF, Johnson G, White D, Larsen R, Cohen NJ, Minihane AM. The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress. Alzheimers Dement (N Y). 2018 Sep 5;4:591-601. doi: 10.1016/j.trci.2018.08.001. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R21647
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.